
Alopecia Areata Studies Sydney SL 102
St Leonards Sydney
Do you have severe Alopecia Areata with extensive hair loss? Join a clinical research study investigating a potential new treatment aimed a promoting hair regrowth and improving quality of life.
By taking part in this study, you may gain early access to new treatment options and contribute to vital medical research.
Description
What to expect
Ages
18 to 60 years old (male) OR 18 to 75 years old (female)
Duration
The study will last up to 40 weeks with 13 in-person clinic visits
Compensation
Participants will be reimbursed for reasonable expenses associated with study visits
Eligibility Criteria
This study may be suitable for you if:
Other criteria applies. A member of our team will check if this study is a good fit for you.
Locations
Alopecia Areata is an autoimmune condition where the body mistakenly attacks hair follicles, causing hair loss on the scalp or body. It can appear as small patches or, in more severe cases, result in total loss of scalp and/or body hair. While not physically harmful, it can have a significant impact on a person's self-esteem and quality of life. Living with alopecia areata can sometimes lead to feelings of anxiety and depression, highlighting the need for more effective treatment options to help people feel confident in their daily lives.
Current treatments for Alopecia Areata, such as corticosteroids, immunotherapy and newer medications, can sometimes help regrow hair, but they are not effective for everyone, and relapses are common.
This study is exploring a potential new treatment that target the immune pathways driving hair loss, aiming for safer and more effective solutions. Specifically, it is testing whether the investigational treatment, can help promote hair regrowth, slow the progression of severe Alopecia Areata, and ultimately improve quality of life for people living with the condition.
Participants will be randomly assigned to receive either the investigational treatment or a placebo. Treatment is given by intravenous infusion (IV) at regular clinic visits under the supervision of trained medical staff.
Throughout the study, you will attend scheduled health assessments that include photography of the scalp to track hair growth, blood tests and thorough medical check-ups. These visits are designed to carefully monitor your progress and overall health. Your safety and well-being will always be our highest priority. An experienced clinical team available to answer questions, provide support, and ensure you feel comfortable and cared for at every stage of participation.
Why join a clinical research study?
-Gain early access to new potential treatments at no cost
- Contribute to research that could help others living with Alopecia Areata
-Receive health checks and advice from our professional medical team
Your privacy is important. All personal information will be kept strictly confidential.
Register your interest today.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research AU is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.